Introduction to the European Society for Antiviral Resistance (ESAR) - - PowerPoint PPT Presentation

Introduction to the European Society for Antiviral Resistance (ESAR)

Bring together scientists and clinicians (Europe) in

• rder to develop activities to study, treat and drug

(HIV) resistant viruses, this all in the broadest sense

• f the word.

Mission of ESAR

EuropeHIVResistance

• Resulting from two successful EC

projects

• Extending collaborations
• restricted number of partners
• limited amount of participating

centers per country

Reasons for ESAR

• Improve knowledge
• Improve diagnostic strategies
• Improve the clinical management of resistant

viruses

• Monitor public health threads

Objectives ESAR

• SPREAD‐surveillance programme
• Collaborative network for scientific studies
• Knowledge Platform
• Guidelines
• Exchange of information
• Training activities
• Improving diagnostic strategies: QC‐programmes

Activities ESAR

• Collaboration
• Responsibility towards science and society
• Transparency
• Independency
• Flexibility

Principles of ESAR

Formal Society

• Non‐profit organisation
• By‐laws will be made available on ESAR website

Associated (voting) membership is individual and

• pen to scientists and clinicians who share the

Aims of the Society. Members per country vote for 2 council members. From the council a board is composed.

Membership

Membership (non voting)

• Non‐Associated Members working for

commercial organisations

• Student Members

• Opportunity to be involved in collaborative

projects with a well established and well

• rganised, very productive group of people

representing whole of Europe

• Opportunity to shape our scientific agenda
• Access to dedicated Members' Zone ESAR website
• ESAR newsletter

Benefits of Membership

Boardmembers

• Charles Boucher (Chairman)
• Annemarie Wensing (Executive Officer)
• Leon Kostrikis (Treasurer)
• Jan Albert
• Bonaventura Clotet
• Osamah Hamouda
• Andrzej Horban
• Dan Otelea
• Mario Poljak
• Jean‐Claude Schmit
• Annemie Vandamme

Council members I

Austria

• 1. Elisabeth Puchhammer
• 2. Benedikt Simon

Belgium

• 1. Linos Vandekerkchove
• 2. To be nominated

Bulgaria

• 1. Danail Beshkov
• 2. Ivailo Alexiev Ivanov

Croatia

• 1. Snjezana Zidovec Lepej
• 2. Josip Begovac

Cyprus ‐ To be nominated Czech Republic ‐ To be nominated Denmark

• 1. Louise Bruun Jørgensen
• 2. Jan Gerstoft

Estonia

• 1. Kai Zilmer
• 2. Kristi Huik

Finland

• 1. Kirsi Liitsola
• 2. To be nominated

France ‐ To be nominated Germany

• 1. Klaus Korn

2.To be nominated Greece

• 1. Dimitrios Paraskevis
• 2. Mina Psichogiou

Hungary ‐ To be nominated Ireland

• 1. Suzie Coughlan
• 2. Cillian de Gascun

Israel

• 1. Zehava Grossman
• 2. Itzchk Levy

Italy ‐ To be nominated Latvia ‐ To be nominated Lithuania ‐ To be nominated Luxembourg

• 1. Danielle Perez‐Bercoff
• 2. Daniel Struck

Council members II

Netherlands

• 1. Rob Schuurman
• 2. To be nominated

Norway

• 1. Birgitta Asjo
• 2. Halvor Rollag

Poland

• 1. Janusz Stanczak
• 2. To be nominated

Portugal

• 1. Ricardo Camacho
• 2. Eugénio Teófilo

Romania

• 1. Simona Paraschiv
• 2. Ana Maria Tudor

Russia

• 1. Natalaya Ladnaya
• 2. Dmitry Kuevda

Serbia

• 1. Maja Stanojevic
• 2. To be nominated

Slovakia

• 1. Danica Stanekova
• 2. To be nominated

Council members III

Slovenia

• 1. Janez Tomazic
• 2. Katja Seme

Spain

• 1. Roger Paredes
• 2. To be nominated

Sweden

• 1. Anders Sonnerborg
• 2. To be nominated

Switzerland ‐ To be nominated United Kingdom

• 1. Annemaria Geretti
• 2. To be nominated

Council members IV

Contributional year March 1 – February 28/29 Fee 2011/2012 10 Euro Payment ‐ via registration EDRW ‐ via invoice

Membership fee

SPECIMEN SPECIMEN

• Annual Scientific Meeting preceeding the

European HIV & Hepatitis Workshop

• General meeting: Board and Council members

ESAR Meetings

www.ESAR‐Society.eu Email:info@ESAR‐Society.eu

Communication Structure